Association of changes in cancer therapy over 3 decades with risk of subsequent breast cancer among female childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS) Journal Article


Authors: Henderson, T. O.; Liu, Q.; Turcotte, L. M.; Neglia, J. P.; Leisenring, W.; Hodgson, D.; Diller, L.; Kenney, L.; Morton, L.; Berrington de Gonzalez, A.; Arnold, M.; Bhatia, S.; Howell, R. M.; Smith, S. A.; Robison, L. L.; Armstrong, G. T.; Oeffinger, K. C.; Yasui, Y.; Moskowitz, C. S.
Article Title: Association of changes in cancer therapy over 3 decades with risk of subsequent breast cancer among female childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS)
Abstract: Key Points: Question: Are the changes in approaches to radiation and chemotherapy treatment for children with cancer over time associated with changes in risk for breast cancer among long-term cancer survivors? Findings: In this longitudinal cohort study of 11 550 female survivors of childhood cancer, the risk of breast cancer modestly decreased with time, which was largely associated with the decreased use of chest radiotherapy, although the risk was tempered by concurrent changes in other therapies. Meaning: Ongoing efforts to both improve survival outcomes and minimize long-term toxic effects in the treatment of childhood cancer were associated with decreasing risk of breast cancer over time. This cohort study examines the association between temporal changes in cancer treatment between 1970 and 1999 and subsequent breast cancer risk among women. Importance: Breast cancer is the most common invasive subsequent malignant disease in childhood cancer survivors, though limited data exist on changes in breast cancer rates as primary cancer treatments have evolved. Objective: To quantify the association between temporal changes in cancer treatment over 3 decades and subsequent breast cancer risk. Design, Setting, and Participants: Retrospective cohort study of 5-year cancer survivors diagnosed when younger than 21 years between 1970 and 1999, with follow-up through December 5, 2020. Exposures: Radiation and chemotherapy dose changes over time. Main Outcomes and Measures: Breast cancer cumulative incidence rates and age-specific standardized incidence ratios (SIRs) compared across treatment decades (1970-1999). Piecewise exponential models estimated invasive breast cancer and ductal carcinoma in situ (DCIS) risk and associations with treatment exposures, adjusted for age at childhood cancer diagnosis and attained age. Results: Among 11 550 female survivors (median age, 34.2 years; range 5.6-66.8 years), 489 developed 583 breast cancers: 427 invasive, 156 DCIS. Cumulative incidence was 8.1% (95% CI, 7.3%-9.0%) by age 45 years. An increased breast cancer risk (SIR, 6.6; 95% CI, 6.1-7.2) was observed for survivors compared with the age-sex-calendar-year-matched general population. Changes in therapy by decade included reduced rates of chest (34% in the 1970s, 22% in the 1980s, and 17% in the 1990s) and pelvic radiotherapy (26%, 17%, and 13% respectively) and increased rates of anthracycline chemotherapy exposures (30%, 51%, and 64%, respectively). Adjusting for age and age at diagnosis, the invasive breast cancer rate decreased 18% every 5 years of primary cancer diagnosis era (rate ratio [RR], 0.82; 95% CI, 0.74-0.90). When accounting for chest radiotherapy exposure, the decline attenuated to an 11% decrease every 5 years (RR, 0.89; 95% CI, 0.81-0.99). When additionally adjusted for anthracycline dose and pelvic radiotherapy, the decline every 5 years increased to 14% (RR, 0.86; 95% CI, 0.77-0.96). Although SIRs of DCIS generally increased over time, there were no statistically significant changes in incidence. Conclusions and Relevance: Invasive breast cancer rates in childhood cancer survivors have declined with time, especially in those younger than 40 years. This appears largely associated with the reduced use of chest radiation therapy, but was tempered by concurrent changes in other therapies.
Journal Title: JAMA Oncology
Volume: 8
Issue: 12
ISSN: 2374-2437
Publisher: American Medical Association  
Date Published: 2022-12-01
Start Page: 1765
End Page: 1774
Language: English
DOI: 10.1001/jamaoncol.2022.4649
PROVIDER: EBSCOhost
PROVIDER: cinahl
PMCID: PMC9562103
PUBMED: 36227603
DOI/URL:
Notes: Accession Number: 160841904 -- Entry Date: In Process -- Revision Date: 20221220 -- Publication Type: Article -- Journal Subset: Peer Reviewed; USA. -- Source: Cinahl
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Chaya S. Moskowitz
    280 Moskowitz